Patents Assigned to Materials Evolution and Development USA Inc.
  • Patent number: 7662767
    Abstract: A method of using modified xanthine molecules as a binding agent is disclosed. Xanthine molecules with at least one substitution of a methyl group at the N1, N3, N7, or N9 position bind to intercalating molecules efficiently. This method can be applied to inhibiting intercalating molecules from binding to nucleic acids, as well as removing intercalating molecules that have been bound to nucleic acids. This method can also be applied to synthesize an efficient drug delivery system for compounds that have low solubility in aqueous media, including anti-neoplastic agents. The method can also be applied to flurosecently labeling nucleic acids.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: February 16, 2010
    Assignee: Materials Evolution and Development USA, Inc.
    Inventor: Mark B. Lyles
  • Patent number: 7641898
    Abstract: A system and method for dispersing living cells onto an area of a subject lacking normal, healthy skin, such as an open wound surface, to form three dimensional epithelial tissue is provided. The cells are dispersed using an air-jet sprayer after being suspended in a soluble media such as dextran. The cells may be dispersed directly onto the area or onto a tissue scaffold or synthetic substance that promotes wound healing.
    Type: Grant
    Filed: March 19, 2004
    Date of Patent: January 5, 2010
    Assignee: Materials Evolution and Development USA, Inc.
    Inventor: Mark B. Lyles
  • Patent number: 7605141
    Abstract: Compositions containing purified nucleic acid wherein the nucleic acid acts as an antioxidant. Such compositions also include materials subject to oxidative damage such as antioxidants, vitamins, lipids, foods and pharmaceuticals. The invention also includes methods for preparing such compositions. These methods include dissolving the nucleic acid and a hydrophilic material in an aqueous solution, which may later be dried or further processed. Additionally, nucleic acid may be coupled with a molecule having hydrophobic and hydrophilic regions and then solubilized in a hydrophobic material. It may also be shaped into small aggregates and added to a hydrophobic material.
    Type: Grant
    Filed: October 6, 2006
    Date of Patent: October 20, 2009
    Assignee: Materials Evolution and Development USA, Inc.
    Inventor: Mark B. Lyles
  • Patent number: 7125859
    Abstract: Compositions containing purified nucleic acid wherein the nucleic acid acts as an antioxidant. Such compositions also include materials subject to oxidative damage such as antioxidants, vitamins, lipids, foods and pharmaceuticals. The invention also includes methods for preparing such compositions. These methods include dissolving the nucleic acid and a hydrophilic material in an aqueous solution, which may later be dried or further processed. Additionally, nucleic acid may be coupled with a molecule having hydrophobic and hydrophilic regions and then solubilized in a hydrophobic material. It may also be shaped into small aggregates and added to a hydrophobic material.
    Type: Grant
    Filed: July 24, 2003
    Date of Patent: October 24, 2006
    Assignee: Materials Evolution and Development USA, Inc.
    Inventor: Mark B. Lyles
  • Patent number: 7056332
    Abstract: Polymers that are biocompatible are useful for various medical purposes such as tissue repair, reconstruction and wound healing. A method and composition for producing a biocompatible polymer formed from nucleic acids is disclosed. The nucleic acid polymer may be used to form a hybrid with an existing polymer to create a copolymer. The nucleic acids may be also be selected to encode particular proteins which may then be expressed in a biological tissue.
    Type: Grant
    Filed: July 24, 2003
    Date of Patent: June 6, 2006
    Assignee: Materials Evolution and Development USA, Inc.
    Inventor: Mark B. Lyles
  • Patent number: 7037304
    Abstract: An implantable infection shield and system for drug delivery in vascular tissue includes a relatively non-biodegradable porous linked fibrous biomaterial which controls and directs cell growth and angiogenesis from adjacent vascular tissue into the implant. Infection shield embodiments stimulate cell growth and angiogenesis from adjacent vascular tissue which effectively blocks passage of pathogenic microorganisms along percutaneously implanted objects. In embodiments for drug delivery, a reservoir of the same biomaterial may contain either (1) a cell culture system enclosed within a porous sealable interior chamber or (2) a biodegradable matrix in which one or more drugs are dispersed. After implantation of a reservoir of the first embodiment in an organism, cultured cells obtain food and oxygen via diffusion in tissue fluid through the porous walls of the interior chamber, while metabolic products, including drugs, diffuse away from the cell culture in an analogous manner.
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: May 2, 2006
    Assignee: Materials Evolution and Development USA, Inc.
    Inventors: Mark B. Lyles, Charles A. McLaughlin, Glenn A. Halff, William A. Mallow
  • Patent number: 6752863
    Abstract: The preferred embodiment of the present invention provides novel and unique fused fibrous compounds for addition to and manufacture of bone and dental cement systems and methods of making the same. The preferred embodiment of the fused fibrous compound material made therefrom comprises a rigid three-dimensional network of fibers fused together at their points of contact wherein said network is greater than 60% by volume void space, has mean pore diameters greater than 10 microns, or both. The fused fibrous compound is preferably manufactured from fibers and a fusion source and is added to the composition in particle form.
    Type: Grant
    Filed: April 4, 2003
    Date of Patent: June 22, 2004
    Assignee: Materials Evolution and Development USA, Inc.
    Inventors: Mark B. Lyles, Kevin D. Rathbun
  • Patent number: 6544324
    Abstract: The preferred embodiment of the present invention provides novel and unique fused fibrous compounds for addition to and manufacture of bone and dental cement systems and methods of making the same. The preferred embodiment of the fused fibrous compound material made therefrom comprises a rigid three-dimensional network of fibers fused together at their points of contact wherein said network is greater than 60% by volume void space, has mean pore diameters greater than 10 microns, or both. The fused fibrous compound is preferably manufactured from fibers and a fusion source and is added to the composition in particle form.
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: April 8, 2003
    Assignee: Materials Evolution and Development USA Inc.
    Inventors: Mark B. Lyles, Kevin D. Rathbun
  • Publication number: 20020120251
    Abstract: An implantable infection shield and system for drug delivery in vascular tissue includes a relatively non-biodegradable porous linked fibrous biomaterial which controls and directs cell growth and angiogenesis from adjacent vascular tissue into the implant. Infection shield embodiments stimulate cell growth and angiogenesis from adjacent vascular tissue which effectively blocks passage of pathogenic microorganisms along percutaneously implanted objects. In embodiments for drug delivery, a reservoir of the same biomaterial may contain either (1) a cell culture system enclosed within a porous sealable interior chamber or (2) a biodegradable matrix in which one or more drugs are dispersed. After implantation of a reservoir of the first embodiment in an organism, cultured cells obtain food and oxygen via diffusion in tissue fluid through the porous walls of the interior chamber, while metabolic products, including drugs, diffuse away from the cell culture in an analogous manner.
    Type: Application
    Filed: September 24, 2001
    Publication date: August 29, 2002
    Applicant: MATERIALS EVOLUTION AND DEVELOPMENT USA, INC.
    Inventors: Mark B. Lyles, Charles A. McLaughlin, Glenn A. Halff, William A. Mallow
  • Patent number: 6291547
    Abstract: The preferred embodiment of the present invention provides novel and unique fused fibrous compounds for addition to and manufacture of bone and dental cement systems and methods of making the same. The preferred embodiment of the fused fibrous compound material made therefrom comprises a rigid three-dimensional network of fibers fused together at their points of contact wherein said network is greater than 60% by volume void space, has mean pore diameters greater than 10 microns, or both. The fused fibrous compound is preferably manufactured from fibers and a fusion source and is added to the composition in particle form.
    Type: Grant
    Filed: October 19, 1998
    Date of Patent: September 18, 2001
    Assignee: Materials Evolution and Development USA Inc.
    Inventors: Mark B. Lyles, Kevin D. Rathbun
  • Patent number: 5951295
    Abstract: The preferred embodiment of the present invention provides novel and unique filler compositions and ceramic enhanced dental materials. The preferred embodiment of the composition and the ceramic dental restorative materials made therefrom comprise a rigid three-dimensional network of fibers fused together at their points of contact wherein said network is greater than 60% by volume void space, has mean pore diameters greater than 10 microns, or both.
    Type: Grant
    Filed: August 8, 1997
    Date of Patent: September 14, 1999
    Assignee: Materials Evolution and Development USA, Inc.
    Inventors: Mark B. Lyles, Ronald G. Ritsco